FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders

FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders FSD Pharma Inc., a biopharmaceutical company dedicated to innovative solutions for neurodegenerative, inflammatory, and metabolic disorders, has released the outcomes of its annual general and special meeting of shareholders held on June 29, 2023. During the meeting, there were 148 shareholders present or rep..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 2.
  • textsms

J&J settles Stelara issue with Teva, Alvotech

Johnson & Johnson (J&J) has settled with Teva and Alvotech over the biosimilar to its most lucrative asset, Stelara. The deal allows AVT04 to enter the US market no later than February 2025. This follows a May 2023 agreement with Amgen over ABP 654, which will hit markets no later than January 1, 2025. Stelara is a human IgG1k monoclonal antibody that targets the IL-12 and IL-23 cytokines. Its p..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 14.
  • textsms